Two myeloma experts express differing views on the role of autologous stem cell transplant as a first-line treatment for multiple myeloma. Dr. Vincent Rajkumar of the Mayo Clinic in Rochester, Minn., said current data are not sufficient to support the use of stem cell transplant as the standard first-line therapy. Dr. Philippe Moreau of the University Hospital Hotel-Dieu in Nantes, France, said current data support the use of routine transplant and that research should focus on which patients will benefit the most from this treatment. The article was published in the journal Leukemia Research.
Published in Brief: